Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 26 clinical trials
Effect of Empagliflozin on Body Composition and Ketones

The purpose of this study is to evaluate changes of body composition induced by Sodium-glucose cotransporter-2 (SGLT2) inhibitor and its metabolic consequence in Korean type 2 diabetes (T2D).

oral hypoglycemic
hypoglycemic agents
type 2 diabetes mellitus
  • 3 views
  • 04 Apr, 2021
  • 1 location
Effect of Ertugliflozin on Cardiac Function in Diabetes

The aim of this study is to investigate the beneficial role of ertugliflozin, a new SGLT2 inhibitor, in cardiac function via measuring GLS as well as other hemodynamic factors using

  • 0 views
  • 05 Apr, 2021
  • 1 location
Effect of Dapagliflozin on Hepatic and Renal Glucose Metabolism Subjects

in detectable amounts in the urine) with an SGLT2 inhibitor, dapagliflozin.

metformin
dapagliflozin
sglt2 inhibitor
sglt2
sulfonylurea
  • 49 views
  • 25 Jan, 2021
  • 1 location
Antidiabetic Triple Therapy Effects on Surrogate Tests After Stroke

, pioglitazone, and an SGLT2 inhibitor (empagliflozin or dapagliflozin or canagliflozin) for 6 months can reduce hsCRP in stroke patients with diabetes mellitus. Methods: This study will be conducted in

glomerular filtration rate
insulin
metformin
pioglitazone
insulin resistance
  • 0 views
  • 25 Jan, 2021
  • 1 location
Ertugliflozin for Functional Mitral Regurgitation

remain high despite standard medical therapy. Randomized trials to explore cardiovascular (CV) benefit of the sodium-glucose co-transporter-2 (SGLT2) inhibitor have been performed and showed a

  • 0 views
  • 26 Jan, 2021
  • 3 locations
The DAPA-MEMRI Trial

failure. Recently, a drug therapy (SGLT2 inhibitor therapy) in patients with diabetes was shown to benefit patients with heart failure but the mechanisms of benefit are unknown. Our hypothesis is

ejection fraction
b-type natriuretic peptide
MRI
heart failure
electrocardiogram
  • 10 views
  • 26 Jan, 2021
  • 1 location
Dapagliflozin Plus Pioglitazone in T1DM

demonstrate that the addition of pioglitazone to SGLT2 inhibitor in T1DM patients produces greater reduction in the HbA1c without increasing risk of ketoacidosis and hypoglycemia.

insulin
continuous glucose monitoring
dapagliflozin
pioglitazone
hypoglycemia
  • 51 views
  • 14 Feb, 2021
  • 1 location
Renal Oxygenation Oxygen Consumption and Hemodynamic Kinetics in Type 2 DIabetes: an Ertugliflozin Study.

Current study will render insight in to the role of renal hypoxia in the diabetic kidney and is able to associate its finding with measurements of renal perfusion and glomerular filtration rate. Moreover, this research will focus on the effects of sodium-glucose cotransporter 2 inhibition on renal tissue oxygenation and …

  • 0 views
  • 11 Apr, 2021
  • 1 location
Effectiveness of Dapagliflozin for Weight Loss

insulin. Dapagliflozin is a selective SGLT2 inhibitor than has shown a sustained effect on the reduction of glycated hemoglobin at 0.4 to 0.8 percent (initial 7.8 to 8.0 percent). Additionally

dyslipidemia
dapagliflozin
sglt2
hdl cholesterol
sleep apnea
  • 18 views
  • 25 Jan, 2021
  • 2 locations
Efficacy of Ipragliflozin Compared With Sitagliptin in Uncontrolled Type 2 Diabetes With Sulfonylurea and Metformin

The objectives of this study are 1) to compare the effect of ipragliflozin 50 mg on glucose-lowering effect with sitagliptin 100 mg in patients with type 2 diabetes mellitus, whose HbA1c level is 7.5% with sulfonylurea and metformin, 2) to investigate changes of other metabolic and cardiovascular risk factors such …

metformin
sitagliptin 100 mg
sulfonylurea
sitagliptin
gliclazide
  • 8 views
  • 08 Apr, 2021
  • 1 location